Export 22 results:
Author [ Title(Desc)] Type Year
Filters: Author is Bailer, Robert T  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
P
A. T. Catanzaro, Koup, R. A., Roederer, M., Bailer, R. T., Enama, M. E., Moodie, Z., Gu, L., Martin, J. E., Novik, L., Chakrabarti, B. K., Butman, B. T., Gall, J. G. D., C King, R., Andrews, C. A., Sheets, R., Gomez, P. L., Mascola, J. R., Nabel, G. J., and Graham, B. S., Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector., J Infect Dis, vol. 194, no. 12, pp. 1638-49, 2006.
B. S. Graham, Koup, R. A., Roederer, M., Bailer, R. T., Enama, M. E., Moodie, Z., Martin, J. E., McCluskey, M. M., Chakrabarti, B. K., Lamoreaux, L., Andrews, C. A., Gomez, P. L., Mascola, J. R., and Nabel, G. J., Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine., J Infect Dis, vol. 194, no. 12, pp. 1650-60, 2006.
M. C. Crank, Gordon, I. J., Yamshchikov, G. V., Sitar, S., Hu, Z., Enama, M. E., Holman, L. S. A., Bailer, R. T., Pearce, M. B., Koup, R. A., Mascola, J. R., Nabel, G. J., Tumpey, T. M., Schwartz, R. M., Graham, B. S., and Ledgerwood, J. E., Phase 1 study of pandemic H1 DNA vaccine in healthy adults., PLoS One, vol. 10, no. 4, p. e0123969, 2015.
A. T. Catanzaro, Roederer, M., Koup, R. A., Bailer, R. T., Enama, M. E., Nason, M. C., Martin, J. E., Rucker, S., Andrews, C. A., Gomez, P. L., Mascola, J. R., Nabel, G. J., and Graham, B. S., Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine., Vaccine, vol. 25, no. 20, pp. 4085-92, 2007.
M. E. Enama, Ledgerwood, J. E., Novik, L., Nason, M. C., Gordon, I. J., Holman, L. S., Bailer, R. T., Roederer, M., Koup, R. A., Mascola, J. R., Nabel, G. J., and Graham, B. S., Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011)., PLoS One, vol. 9, no. 3, p. e91366, 2014.
J. E. Ledgerwood, Zephir, K., Hu, Z., Wei, C. - J., Chang, L., Enama, M. E., Hendel, C. S., Sitar, S., Bailer, R. T., Koup, R. A., Mascola, J. R., Nabel, G. J., and Graham, B. S., Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect., J Infect Dis, vol. 208, no. 3, pp. 418-22, 2013.
R. A. Koup, Roederer, M., Lamoreaux, L., Fischer, J., Novik, L., Nason, M. C., Larkin, B. D., Enama, M. E., Ledgerwood, J. E., Bailer, R. T., Mascola, J. R., Nabel, G. J., and Graham, B. S., Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses., PLoS One, vol. 5, no. 2, p. e9015, 2010.
S
T. A. Crowell, Colby, D. J., Pinyakorn, S., Sacdalan, C., Pagliuzza, A., Intasan, J., Benjapornpong, K., Tangnaree, K., Chomchey, N., Kroon, E., de Souza, M. S., Tovanabutra, S., Rolland, M., Eller, M. A., Paquin-Proulx, D., Bolton, D. L., Tokarev, A., Thomas, R., Takata, H., Trautmann, L., Krebs, S. J., Modjarrad, K., McDermott, A. B., Bailer, R. T., Doria-Rose, N., Patel, B., Gorelick, R. J., Fullmer, B. A., Schuetz, A., Grandin, P. V., O'Connell, R. J., Ledgerwood, J. E., Graham, B. S., Tressler, R., Mascola, J. R., Chomont, N., Michael, N. L., Robb, M. L., Phanuphak, N., and Ananworanich, J., Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial., Lancet HIV, vol. 6, no. 5, pp. e297-e306, 2019.
U. N. Sarwar, Costner, P., Enama, M. E., Berkowitz, N., Hu, Z., Hendel, C. S., Sitar, S., Plummer, S., Mulangu, S., Bailer, R. T., Koup, R. A., Mascola, J. R., Nabel, G. J., Sullivan, N. J., Graham, B. S., and Ledgerwood, J. E., Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial., J Infect Dis, vol. 211, no. 4, pp. 549-57, 2015.
H. Kibuuka, Berkowitz, N. M., Millard, M., Enama, M. E., Tindikahwa, A., Sekiziyivu, A. B., Costner, P., Sitar, S., Glover, D., Hu, Z., Joshi, G., Stanley, D., Kunchai, M., Eller, L. Anne, Bailer, R. T., Koup, R. A., Nabel, G. J., Mascola, J. R., Sullivan, N. J., Graham, B. S., Roederer, M., Michael, N. L., Robb, M. L., and Ledgerwood, J. E., Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial., Lancet, vol. 385, no. 9977, pp. 1545-54, 2015.
C. Carter, Houser, K. V., Yamshchikov, G. V., Bellamy, A. R., May, J., Enama, M. E., Sarwar, U., Larkin, B., Bailer, R. T., Koup, R., Chen, G. L., Patel, S. M., Winokur, P., Belshe, R., Dekker, C. L., Graham, B. S., and Ledgerwood, J. E., Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial., PLoS One, vol. 14, no. 9, p. e0222178, 2019.
W. Jaoko, Karita, E., Kayitenkore, K., Omosa-Manyonyi, G., Allen, S., Than, S., Adams, E. M., Graham, B. S., Koup, R. A., Bailer, R. T., Smith, C., Dally, L., Farah, B., Anzala, O., Muvunyi, C. M., Bizimana, J., Tarragona-Fiol, T., Bergin, P. J., Hayes, P., Ho, M., Loughran, K., Komaroff, W., Stevens, G., Thomson, H., Boaz, M. J., Cox, J. H., Schmidt, C., Gilmour, J., Nabel, G. J., Fast, P., and Bwayo, J., Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa., PLoS One, vol. 5, no. 9, p. e12873, 2010.
L. - J. Chang, Dowd, K. A., Mendoza, F. H., Saunders, J. G., Sitar, S., Plummer, S. H., Yamshchikov, G., Sarwar, U. N., Hu, Z., Enama, M. E., Bailer, R. T., Koup, R. A., Schwartz, R. M., Akahata, W., Nabel, G. J., Mascola, J. R., Pierson, T. C., Graham, B. S., and Ledgerwood, J. E., Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial., Lancet, vol. 384, no. 9959, pp. 2046-52, 2014.
J. Parrino, McCurdy, L. H., Larkin, B. D., Gordon, I. J., Rucker, S. E., Enama, M. E., Koup, R. A., Roederer, M., Bailer, R. T., Moodie, Z., Gu, L., Yan, L., and Graham, B. S., Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals., Vaccine, vol. 25, no. 8, pp. 1513-25, 2007.
J. E. Martin, Louder, M. K., Holman, L. S. A., Gordon, I. J., Enama, M. E., Larkin, B. D., Andrews, C. A., Vogel, L., Koup, R. A., Roederer, M., Bailer, R. T., Gomez, P. L., Nason, M., Mascola, J. R., Nabel, G. J., and Graham, B. S., A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial., Vaccine, vol. 26, no. 50, pp. 6338-43, 2008.